Volume 4.07 | Feb 26

Hematopoiesis News 4.07 February 26, 2013
Hematopoiesis News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Hematopoietic Stem Cells and Early Lymphoid Progenitors Occupy Distinct Bone Marrow Niches
Researchers assessed the physiological sources of the chemokine CXCL12 for hematopoietic stem cells and restricted progenitor maintenance. Cxcl12DsRed knock-in mice (DsRed-Express2 recombined into the Cxcl12 locus) showed that Cxcl12 was primarily expressed by perivascular stromal cells and, at lower levels, by endothelial cells, osteoblasts and some hematopoietic cells. [Nature] Abstract | Press Release

Free Wallchart: Identification Of Colonies Derived From Mouse Hematopoietic Progenitors
PUBLICATIONS (Ranked by impact factor of the journal)


CXCL12 in Early Mesenchymal Progenitors Is Required for Hematopoietic Stem-Cell Maintenance
Scientists selectively deleted Cxcl12 from candidate niche stromal cell populations and characterized the effect on hematopoietic progenitor cells. Deletion of Cxcl12 from mineralizing osteoblasts has no effect on hematopoietic stem cells or lymphoid progenitors. [Nature] Abstract | Press Release

Xist RNA Is a Potent Suppressor of Hematologic Cancer in Mice
Researched deleted Xist in the blood compartment of mice and demonstrate that mutant females develop a highly aggressive myeloproliferative neoplasm and myelodysplastic syndrome with 100% penetrance. Significant disease components include primary myelofibrosis, leukemia, histiocytic sarcoma, and vasculitis. Xist-deficient hematopoietic stem cells show aberrant maturation and age-dependent loss. [Cell]
Abstract | Graphical Abstract

Attenuation of AML1-ETO Cellular Dysregulation Correlates with Increased Leukemogenic Potential
Scientists investigated the role of two AML1-ETO C-terminal-interacting proteins, N-CoR, a transcriptional co-repressor, and SON, a splicing/transcription factor required for cell cycle progression, in AML1-ETO-induced leukemia development. [Blood] Abstract

DNA Damage in Stem Cells Activates p21, Inhibits p53, and Induces Symmetric Self-Renewing Divisions
Researchers showed that irradiation of hematopoietic and mammary stem cells up-regulates the cell cycle inhibitor p21, a known target of p53, which prevents p53 activation and inhibits p53 basal activity, impeding apoptosis and leading to cell cycle entry and symmetric self-renewing divisions. [Proc Natl Acad Sci USA] Abstract

The Novel Arsenical Darinaparsin Circumvents BRG1-Dependant, HO-1-Mediated Cytoprotection in Leukemic Cells
Scientists observed that, unlike arsenic trioxide (ATO), darinaparsin does not induce HO-1, even though it induces expression of other nuclear factor (erythroid-derived 2)-like 2-dependant detoxifying enzymes to a greater extent than ATO, in both cancer cell lines and patient-derived leukemic cells. [Leukemia] Abstract

Hematopoietic Protein-1 Regulates the Actin Membrane Skeleton and Membrane Stability in Murine Erythrocytes
The authors utilized mice lacking Hematopoietic Protein-1 (Hem-1) expression due to a non-coding point mutation in the Hem1 gene to show that absence of Hem-1 results in microcytic, hypochromic anemia characterized by abnormally shaped erythrocytes with aberrant F-actin foci and decreased lifespan. [PLoS One] Full Article


T-Cell-Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
Outcomes of 271 consecutive patients undergoing T-cell-replete first allogeneic hematopoietic cell transplantation for hematologic malignancies performed contemporaneously at a single center were compared. Overall and disease-free survival were adjusted for effects of significant patient-, disease-, and transplantation-related covariates using a stratified Cox model. [J Clin Oncol] Abstract

Phase II Clinical Trial of Rapamycin-Resistant Donor CD4+ Th2/Th1 (T-Rapa) Cells after Low-Intensity Allogeneic Hematopoietic Cell Transplantation
Researchers performed a Phase II multi-center clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 cells after allogeneic matched-sibling donor hematopoietic cell transplantation for therapy of refractory hematologic malignancy. [Blood] Abstract

Phase II Study of Arsenic Trioxide Followed by Autologous Hematopoietic Cell Transplantation for Relapsed Acute Promyelocytic Leukemia
The authors conducted a Phase II study to evaluate the efficacy and feasibility of a sequential treatment consisting of induction and consolidation with arsenic trioxide, peripheral blood stem cell harvest after high-dose cytarabine chemotherapy, and autologous hematopoietic cell transplantation. [Blood] Abstract

New StemSpan(TM) SFEM II - for optimal CD34+ cell expansion of bone marrow and cord blood cells

In Utero Hematopoietic Cell Transplantation – Recent Progress and the Potential for Clinical Application
The authors discuss recent experimental progress toward overcoming the barriers to allogeneic engraftment and new therapeutic strategies that may hasten clinical application. [Cytotherapy] Abstract

Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
Pluristem Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has designated Pluristem’s placental expanded cells orphan drug status for the treatment of aplastic anemia. [Pluristem Therapeutics Inc.] Press Release

Gentium Provides Update on the Review of Defibrotide Marketing Authorization
Gentium S.p.A. announced that the Company had presented an oral explanation at the European Medicines Agency’s Committee for Medicinal Products for Human Use as part of its Marketing Authorization Application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy. [Gentium S.p.A.] Press Release


Expanding Public Access to the Results of Federally Funded Research
In a policy memorandum, Office of Science and Technology Policy Director John Holdren has directed Federal agencies with more than $100 million in R&D expenditures to develop plans to make the published results of federally funded research freely available to the public within one year of publication and requiring researchers to better account for and manage the digital data resulting from federally funded scientific research. [Office of Science and Technology Policy, The White House, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW SMi’s Cell Culture 2013
July 3-4, 2013
London, United Kingdom

Visit our events page to see a complete list of events in the hematopoietic community.


Postdoctoral Position – Gene Regulation in the Hematopoietic and Immune Systems (Lund University)

Postdoctoral Position – Hematopoietic and Malignant Stem Cells (Istanbul University)

Postdoctoral Position – Stem Cell Biology (Washington University of Medicine)

Postdoctoral Research Associate – Stem Cell Biology and Epigenetics (University of Wisconsin)

Postdoctoral Position – Myeloproliferative Neoplasms (Mount Sinai Medical Center)

Postdoctoral Position – Stem Cell Research (University of Washington)

PhD Studentship (University Medical Center Groningen)

PhD Studentship – Hematopoietic Development and Bioinformatics (Karolinska Institute, Department of Laboratory Medicine)

Postdoctoral Position – Hematopoietic Stem Cells and Stem Cell Aging (Cincinnati Children’s Hospital Research Foundation)

Lecturer or Reader – Associate Professor (University of Reading)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada